Abstract
Introduction/BackgroundFollowing implementation of targeted therapies to first-line treatment, repeated use of bevacizumab and/or PARPi is often not approved nor has been conclusively proven efficacious for all patients with recurrent ovarian...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Paper Title
Journal
Date
